RWJBarnabas Health and Rutgers Cancer Institute of New Jersey break ground on Jack & Sheryl Morris Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with the New Brunswick Development Corporation, broke ground on the state’s first freestanding cancer hospital. 

At the ceremony, it was also announced that the 510,000-square-foot structure will be named the Jack and Sheryl Morris Cancer Center in recognition of the philanthropic leadership of Jack Morris, who has been a longtime supporter and pillar in New Brunswick development, and his wife, Sheryl.

The 12-story facility, to be located on Somerset Street, will house inpatient, outpatient and ancillary services, as well as state-of-the-art laboratories where research faculty can provide hands-on educational opportunities for students, and enable physician-scientists to translate scientific findings directly to patients. 

The Jack and Sheryl Morris Cancer Center will enable ease of access for imaging and other diagnostic tests, treatment and follow-up exams all in one space. It will also have the capacity to offer wellness and education resources including offerings catered specifically to the needs of cancer survivors. The estimated project cost is $750 million.

The facility, which will be positioned adjacent to the existing Rutgers Cancer Institute building and Robert Wood Johnson University Hospital, also will house state-of-the-art research laboratories. 

The project is expected to be completed in 2024.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login